

# Judit Morello

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2945001/judit-morello-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

931  
citations

18  
h-index

29  
g-index

49  
ext. papers

1,062  
ext. citations

4.3  
avg, IF

3.54  
L-index

#	Paper	IF	Citations
47	Synthetic Red Blood Cell-Specific Glycolytic Intermediate 2,3-Diphosphoglycerate (2,3-DPG) Inhibits Development .. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2022</b> , 12, 840968	5.9	0
46	A simple method to measure sulfonation in man using paracetamol as probe drug. <i>Scientific Reports</i> , <b>2021</b> , 11, 9036	4.9	0
45	AHR canonical pathway: in vivo findings to support novel antihypertensive strategies. <i>Pharmacological Research</i> , <b>2021</b> , 165, 105407	10.2	3
44	Aryl Hydrocarbon Receptor and Cysteine Redox Dynamics Underlie (Mal)adaptive Mechanisms to Chronic Intermittent Hypoxia in Kidney Cortex. <i>Antioxidants</i> , <b>2021</b> , 10,	7.1	1
43	A Mechanistic-Based and Non-invasive Approach to Quantify the Capability of Kidney to Detoxify Cysteine-Disulfides. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1306, 109-120	3.6	1
42	Metabolic Dysfunction and Asthma: Current Perspectives. <i>Journal of Asthma and Allergy</i> , <b>2020</b> , 13, 237-247	4.7	10
41	The mercapturomic profile of health and non-communicable diseases. <i>High-Throughput</i> , <b>2019</b> , 8,	4.3	4
40	Mass Spectrometry-Based Methodologies for Targeted and Untargeted Identification of Protein Covalent Adducts (Adductomics): Current Status and Challenges. <i>High-Throughput</i> , <b>2019</b> , 8,	4.3	9
39	A Metabolomics-Inspired Strategy for the Identification of Protein Covalent Modifications. <i>Frontiers in Chemistry</i> , <b>2019</b> , 7, 532	5	1
38	Mercapturate Pathway in the Tubulocentric Perspective of Diabetic Kidney Disease. <i>Nephron</i> , <b>2019</b> , 143, 17-23	3.3	12
37	Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy. <i>Kidney International Reports</i> , <b>2019</b> , 4, 494-499	4.1	9
36	Usefulness of zebrafish larvae to evaluate drug-induced functional and morphological renal tubular alterations. <i>Archives of Toxicology</i> , <b>2018</b> , 92, 411-423	5.8	22
35	Zebrafish Larvae Are a Suitable Model to Investigate the Metabolic Phenotype of Drug-Induced Renal Tubular Injury. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1193	5.6	8
34	The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicals. <i>Free Radical Biology and Medicine</i> , <b>2018</b> , 129, 559-568	7.8	6
33	Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge. <i>Drug Metabolism Reviews</i> , <b>2017</b> , 49, 357-371	7	18
32	Exploratory metabolomics study of the experimental opisthorchiasis in a laboratory animal model (golden hamster, <i>Mesocricetus auratus</i> ). <i>PLoS Neglected Tropical Diseases</i> , <b>2017</b> , 11, e0006044	4.8	10
31	Effect of Suboptimal Sampling and Handling Conditions on Urinary Metabolic Profiles. <i>Chromatographia</i> , <b>2015</b> , 78, 429-434	2.1	2

30	Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19682	5.4	3
29	Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 376-83	7	30
28	Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 156-64	1.6	17
27	Noncirrhotic portal hypertension in HIV infection. <i>Current Opinion in Infectious Diseases</i> , <b>2011</b> , 24, 12-8	5.4	25
26	Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 457-77	5.5	28
25	Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , <b>2011</b> , 27, 1043-5	1.6	11
24	Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 1291-5	11.6	13
23	Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 1567-9	5.1	31
22	Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202, 1185-91	7	31
21	Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C. <i>AIDS Research and Human Retroviruses</i> , <b>2010</b> , 26, 419-24	1.6	5
20	Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1647-9	5.9	18
19	Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. <i>Aids</i> , <b>2010</b> , 24, 777-9	3.5	10
18	Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. <i>HIV Clinical Trials</i> , <b>2010</b> , 11, 197-204		28
17	Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfecting patients with prior nonresponse or relapse. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 53, 364-8	3.1	24
16	The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 242-4	3.2	
15	Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 4153-8	5.9	6
14	Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, e108-16	11.6	200
13	Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities. <i>Drug Metabolism Letters</i> , <b>2009</b> , 3, 67-9	2.1	

12	Raltegravir and etravirine are active against HIV type 1 group O. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 225-7	1.6	39
11	Role of atazanavir in the treatment of HIV infection. <i>Therapeutics and Clinical Risk Management</i> , <b>2009</b> , 5, 99-116	2.9	11
10	Association between tipranavir plasma levels and virological response in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 389-91	1.6	3
9	Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 821-5	1.6	31
8	Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 816-22	5.1	30
7	Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 1174-80	5.1	75
6	Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. <i>Aids</i> , <b>2008</b> , 22, 2535-7	3.5	30
5	Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 200-5	5.1	58
4	Distinct Hepatitis C virus Kinetics in HIV-Infected Patients Treated with Ribavirin plus Either Pegylated Interferon $\alpha$ a or $\alpha$ b. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 511-517	1.6	5
3	Drug interactions of tipranavir, a new HIV protease inhibitor. <i>Drug Metabolism Letters</i> , <b>2007</b> , 1, 81-4	2.1	8
2	Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 839-50	4	18
1	Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 802-6	3.2	27